IFN-γ-induced microRNA-29b up-regulation contributes to keratinocyte apoptosis in atopic dermatitis through inhibiting Bcl2L2

Chaoying Gu1*, Yin Li2*, Jinfeng Wu1, Jinhua Xu1

1Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China; 2Department of Emergency, Huadong Hospital, Fudan University, Shanghai, China. *Equal contributors.

Received July 10, 2017; Accepted August 24, 2017; Epub September 1, 2017; Published September 15, 2017

Abstract: Recent evidence has suggested that microRNAs (miRNAs) may play a significant role in the pathogenesis of inflammatory skin conditions such as atopic dermatitis (AD). The aim of the present study was to evaluate the potential functions of miRNAs in AD and to identify the underlying mechanisms. We firstly analyzed miRNA expression in the skin lesions of patients with AD using microarray analysis. Validation analysis was performed in skin biopsy specimens and in serum using quantitative reverse transcription PCR (qRT-PCR). The relationship between microRNA-29b (miR-29b) and development of AD was further explored. Subsequently, gain- and loss-of-function studies were performed to determine the functions of miR-29b in interferon-γ (IFN-γ)-induced keratinocytes (KCs) apoptosis. Further bioinformatics analysis and luciferase reporter assays were performed to predict its target genes, then the effects of miR-29b on the expression of BCL2-like2 (Bcl2L2) were investigated using qRT-PCR and western blot analysis. Finally, KCs were transfected with miR-29b mimics or Bcl2L2 siRNA (si-Bcl2L2) to explore the mechanism by which miR-29b plays in the pro-apoptotic roles in IFN-γ-treated keratinocytes. The miR-29b was found to be one of the most significantly up-regulated miRNAs in the skin lesions of patients with AD, as compared with healthy control and its expression was statistically associated with the development of AD. We, therefore, selected miR-29b as a candidate miRNA and investigated its function. Our in vitro data showed that the keratinocytes apoptosis induced by IFN-γ-duced by IFN-ptosis induced by IFN-vestigated its function. Our stically associated with the deve particular, we identified Bcl2L2 as a direct target of miR-29b. More importantly, siRNA-induced knockdown of Bcl2L2 attenuated the protective effects of miR-29b inhibition on keratinocytes apoptosis. These results suggested that miR-29b knockdown may play an important role in preventing cell apoptosis in IFN-ctreated keratinocytes, and these effects might be partially through regulation of Bcl2L2. These findings revealed that the miR-29b/Bcl2L2 regulatory axis was involved in the pathogenesis of AD and suggested that knockdown of miR-29b might be a novel therapeutic target for AD.

Keywords: Atopic dermatitis, microRNA-29b, keratinocyte, apoptosis, IFN-optosis

Introduction

Atopic dermatitis (AD) is a chronic and relapsing skin disease that is characterized by the epidermal barrier dysfunction, skin inflammation and apoptosis of keratinocytes [1, 2]. Despite the great efforts that have been made to improve the functional outcome of patients with AD, advances in therapy for AD have, thus far, been limited. Several studies reported that keratinocytes apoptosis induced by activated T cells is one of the major mechanisms in the pathogenesis of AD [2, 3]. IFN–γ regulates the expression of several genes involved in keratinocyte apoptosis [4]. Monitoring keratinocyte apoptosis in the treatment of atopic dermatitis is important for successfully managing AD [4]. However, the precise mechanisms of such apoptosis are not currently fully understood.

MicroRNAs (miRNAs) are small non-coding RNAs about 18–22 nucleotides in length that regulate gene expression at the transcriptional and/or post-transcriptional levels by binding to the 3’UTR of the target gene mRNA [5]. The alteration of miRNAs expression plays important roles in various cellular processes, such as
MicroRNA-29b promotes keratinocyte apoptosis in AD

proliferation, apoptosis, differentiation and metabolism [6]. Several miRNAs, including miR-21, miR-146, miR-155 and miR-223, have been found to be differentially expressed in skin samples of AD patients [7]. In addition, some miRNAs have also been shown to have favorable diagnostic and prognostic determinations for AD patients [8, 9]. A number of microRNAs have been shown to functionally participate in the keratinocyte apoptosis. MiRNAs such as miR-130 [10] and miR-21 [11] inhibited keratinocyte apoptosis, whereas miR-125b [12] and miR-330-5p [13] promoted keratinocyte apoptosis. Like many other microRNAs, miR-29b, a member of miR-29 family, has been shown to be involved in the apoptosis in various types of cells [14-16]. Most interestingly, miR-29b has been shown to be one of the most up-regulated miRNAs in melanoma cells after IFN-γ IFN-γ-sh [17]. A similar change pattern was observed in colorectal cancer (CRC) treated with IFN-γ [18]. However, little is known whether miR-29b is also involved in the apoptosis of keratinocytes induced by IFN-γ, and how it works.

In the present study, we identified miR29b was one of the most significantly up-regulated miRNAs in the skin lesions of patients with AD, as compared with healthy control and its expression was associated with the development of AD. Furthermore, knockdown of miR-29b was found to inhibit IFN-γ-induced keratinocyte apoptosis, which might be attributed to the up-regulation of its target gene, Bcl2L2.

Materials and methods

Specimens collection

Lesional skin biopsy specimens (diameter, 4 mm) were obtained from 12 healthy control subjects (7 women, 5 men, age, 19-42 years), 21 patients with AD (10 men, 11 women, age 18-41 years). Patients with atopic dermatitis were identified according to the criteria defined by Hanifin and Rajka [19]. Blood samples were obtained from 30 healthy control subjects (17 women, 13 men, age, 18-40 years), 30 patients with AD (14 women, 16 men, age, 19-39 years). The specimens were immediately frozen in liquid nitrogen and stored at -80°C for further use. The study was approved by the Ethical Review Committees on Human Research of the University of Tartu and the University of Szeged. All participants signed a written informed consent form. None of the patients had been treated with systemic antihistamines and/or topical corticosteroids for at least 1 week before study participation.

Cell culture

Primary human keratinocytes were isolated from healthy skin as described previously [20, 21] and cultured to 80% of confluency in keratinocyte serum-free medium supplemented with keratinocyte growth supplement (Invitrogen, Carlsbad, CA, USA). Human 293T embryonic kidney cells were purchased from the American Type Culture Collection (Manassas, VA, USA) and maintained in Dulbecco’s modified Eagle’s medium (Invitrogen) containing 10% fetal bovine serum (Invitrogen) and 1/100 streptomycin-penicillin mix (Sigma-Aldrich, St. Louis, MO, USA). All cells were cultured at 37°C in a humidified atmosphere containing 5% CO₂.

MicroRNA expression profiling assay

MiRNA profiling of lesional skin biopsy specimens was performed with the 7th generation of miRCURY™ LNA Array (v.18.0, Exiqon) as described previously [22]. Expressed data were normalized using the median normalization. After normalization, significant differentially expressed miRNAs were identified through Volcano plot filtering. Hierarchical clustering was performed using MEV software (v4.6, TIGR). The miRNAs were considered to be significantly differentially expressed between the two groups (AD patient versus healthy control) if the fold changes (FC) was > 2.0 and the P value was <0.05.

Quantitative reverse transcription-PCR (qRT-PCR)

Total RNA was isolated from the lesional skin biopsy specimens, sera and keratinocytes using the TRizol reagents (Invitrogen, CA, USA) following the manufacturer’s instructions, and first-strand cDNA was generated using Script™ cDNA Synthesis Kit (Bio-Rad Laboratories). Real-time PCR was then performed on an Applied Biosystems 7900HT cycler using Super Real PreMix Plus (Tiangen, China) or the miRcute miRNA qPCR Detection Kit (Tiangen, China) according to the manufacturer’s guidelines. U6 and GAPDH functioned as normalization control in the expression analysis of miR-
MicroRNA-29b promotes keratinocyte apoptosis in AD

29b and BCL2L2, respectively. The relative expression of RNAs was calculated using the \(2^{-\Delta\Delta Ct}\) method. Each reaction was conducted in triplicate.

**Transfection**

The miR-29b mimics, miR-29b inhibitor and negative control (NC) were synthesized by GenePharma (Shanghai, China). The Bcl2L12 siRNA and NC siRNA were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Primary human keratinocytes transfection was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions.

**Apoptosis analysis**

Flow cytometry was used to detect the effect of miR-29b on cell apoptosis. 24 h after transfection, cells were harvested, washed with ice-cold PBS, and re-suspended in 500 μl of binding buffer. After the density of the cells was adjusted to 5 × 10^6/ml, cells were incubated with 5 μl Annexin V and 5 μl propidium iodide (PI) (BD Biosciences, San Jose, CA) at room temperature in the dark for 15 min. Apoptotic keratinocytes were quantified by BD FACSCalibur Flow Cytometer (BD Biosciences).

**Cell viability assay**

3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was performed to detect the effect of miR-29b on cell proliferation. Briefly, cells were seeded in 96-well plates at a density of 5 × 10^3 cells/well/100 µl of media. Cells were treated with 10 µM MTT solution for 4 h. Then, the absorbance at a wavelength of 570 nm was detected by a microplate reader (Bio-Tek Instruments, Winooski, VT, USA).

**Western blot assay**

Western blot was performed as previously described [23]. The membranes were blocked with rabbit primary antibody against Bcl-2L2, cleaved-caspase 3 and total caspase-3 (1:1000, Santa Cruz, CA, USA) or β-actin (1:2000, Santa Cruz, CA, USA) overnight at 4° or 4°C against Bcl2L2, cleaved- by a microplgG-HRP secondary antibody (1:2000, Santa Cruz, CA, USA) at room temperature for 1 h, and then visualized by using an enhanced chemiluminescence detection method (Thermo Fisher Scientific, Waltham, MA, USA). Relative intensities were determined by Quantity One 4.6.2 software (Bio-Rad, CA, USA).

**Luciferase assays**

A cDNA fragment of the Bcl2L2 3’-UTR mRNA containing the seed sequence of the miR-29b-binding site or a mutated binding site was cloned into the pmirGLO dual-luciferase vector (Promega, Madison, WI, USA). The constructed dual-luciferase vector was co-transfected with miR-29b mimics, miR-29b inhibitor or NC into 293T cells. The cells were harvested and lysed 24 h later, and the luciferase activity was measured by the Dual-Luciferase Assay System (Promega) in accordance to the manufacturer’s instructions.

**Caspase-3 activity assay**

Activity of caspase-3 was performed as previously described [24]. Briefly, after transfection, keratinocytes were lysed and re-suspended in 50 µg of ice-cold cell lysis buffer for 30 min. Caspase-3 activity was determined using a Caspase-3 activity kit (Beyotime, China). Caspase-3 activity was quantified in the samples with a microplate spectrophotometer (Biotek) at an absorbance of 405 nm.

**Statistical analysis**

Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, Inc., San Diego, CA, USA). Differences were analyzed with the Student’s t-test between two groups or with one-way ANOVA among four groups. Correlation analyses were made with Spearman’s correlation analysis test. A P-value of less than 0.05 was considered statistically significant.

**Results**

**MiR-29b was up-regulated in the lesional skin and serum of AD patients**

To elucidate the expression of miRNAs associated with AD, we performed a miRNA microarray on skin samples from AD patients and healthy individuals. Using the screening criteria of FC > 2 and P<0.05, we identified 37 differentially expressed miRNAs in AD patients versus healthy individuals (Figure 1A). Among the 37
miRNAs, 11 were up-regulated and 26 were down-regulated. Based on several studies that miR-29b could induce cell apoptosis in many types of cells [14-16], we tested if miR-29b was also involved in the progression of AD. In the first step, we examined the expression of miR-29b in 21 lesional skin biopsy specimens derived from patients with AD and 12 skin biopsy specimens derived from healthy donors using quantitative real-time PCR (qRT-PCR). According to qRT-PCR analysis, miR-29b expression was markedly increased in skin biopsy specimens derived from healthy donors as compared with that in healthy control group (Figure 1B). qRT-PCR analysis was also applied to detect miR-29b expression in 30 sera from AD patients and 30 sera from healthy controls. The expression of miR-29b was significantly increased in sera from AD patients, as compared with that in healthy control group. In addition, the miR-29b expression levels were positively correlated with the AD disease severity score, as measured by the SCORAD system (Spearman r=0.8006, P<0.001; Figure 1C). These results suggest that miR-29b may play important roles in AD progression and may serve as potential biomarkers for the early detection of AD.

Knockdown of miR-29b suppressed INF-γ induced apoptosis in keratinocyte

It is reported that INF-γ increased the expression of miR-29b in melanoma cells and colon cancer cells after IFN-γ treatment [17, 18] and
miR-29b plays an important role in FN-3 “1579” of miR-29b in [18]. To examine whether IFN-γ affected miR-29b in keratinocytes, keratinocytes were treated with IFN-γ (10 ng/ml for 12 h, 24 h and 48 h), and then miR-29b was measured by qRT-PCR. As shown in Figure 2A, miR-29b was strongly up-regulated by IFN-γ in a time-dependent manner. Subsequently, miR-29b was over-expressed or knocked down in IFN-γ stimulated keratinocytes prior to the assessment of cell viability and cell apoptosis. As shown in Figure 2B, MTT assay revealed that the cell viability of keratinocytes was inhibited at 24 h and 48 h after IFN-γ treatment. MTT assay revealed that the cell viability of keratinocytes was inhibited at 24 h and 48 h after IFN-γ treatment. To examine whether IFN-γ affected miR-29b in keratinocytes, keratinocytes were transfected with miR-29b mimics, miR-29b inhibitor and miRNA negative control. The expressions of cleaved-caspase-3 and total caspase-3 were analyzed by Western Blot. As shown in Figure 2C, Western blot assay showed that the expression of cleaved caspase 3 was markedly increased in miR-29b mimics group, while the expression of cleaved caspase 3 was significantly decreased in miR-29b inhibitor group (Figure 2C). In addition, the level of pro caspase 3 has no difference in both groups. In response to this finding, we assessed the role of miR-29b in IFN-γ induced apoptosis and found that over-expression of miR-29b aggravated the...
MicroRNA-29b promotes keratinocyte apoptosis in AD

apoptosis induced by IFN-r, whereas inhibition of miR-29b could attenuate the apoptosis mediated by IFN-e (Figure 2D, 2E). These data indicated that the knockdown of miR-29b could protect keratinocytes from apoptosis induced by IFN-F.

**MiR-29b targets and inhibits BCL2L2 gene expression**

To assess the role of miR-29b in regulating the apoptosis in keratinocytes, bioinformatics tools were used to search for the potential targets of miR-29b. According to the results of these analyses, we focused on BCL2L2, an important anti-apoptotic protein since it has recently been found to be a target gene of miR-29b in neuronal cells [16] and human glioblastoma cells [25]. Thus, BCL2L2 was selected for further investigation. The binding sites between BCL2 and miR-29b are illustrated in Figure 3A. Dual-luciferase reporter assay was performed to test whether miR-29b targets BCL2L2. The results showed that over-expression of miR-29b significantly decreased the luciferase activity of wt-BCL2L2-3'UTR, whereas knockdown of miR-29b increased the luciferase activity of wt-BCL2L2-3'UTR. Likewise, cells co-transfected with miR-29b mimics, miR-29b inhibitor, and BCL2L2-mut-3'UTR, showed no obvious change in their luciferase activity (Figure 3B). In addition, we explored whether miR-29b could modulate the expression of BCL2L2. As shown in Figure 3C and 3D, the mRNA and protein levels of BBCL2L2 was decreased after over-expression of miR-29b, whereas it increased after inhibition of miR-29b, supporting that miR-29b can regulate BCL2L2 expression in vitro. These results demonstrated that BCL2L2 is a potential target of miR-29b in keratinocytes.

MiR-29b mediated the expression of BCL2L2 is involved in the IFN-n-regulated cell proliferation and apoptosis of keratinocytes

Following on from the above findings, we sought to further explore whether miR-29b/BCL2L2 axis was involved in pro-apoptotic effect of...
MicroRNA-29b promotes keratinocyte apoptosis in AD

IFN-α in keratinocytes. First, miR-29b inhibitor and si-BCL2L2 were co-transfected into IFN-d into IFN-keratinocytes, and the cell viability of keratinocytes was compared with that in the IFN-t in the IFN-mpared with that in the IFN-γ with that in the IFN-γ with that in the IFN-γ with the cell viability so that, when administered together, cell viability was significantly decreased than in the miR-29b inhibitor + IFN-γ group (Figure 4A). The caspase-3 activity was decreased in the miR-29b inhibitor + IFN-γ group, as compared with the IFN-γ group, and that this inhibitory effect was removed by the co-administration of si-BCL2L2 (Figure 4B). Similarly, we also observed that si-BCL2L2 could reverse the inhibitory effect of miR-29b inhibitor on the apoptosis and the expression of cleaved caspase 3 (Figure 4C, 4D). Collectively, we concluded that knockdown of miR-29b could inhibit the apoptosis in IFN-γ-treated keratinocytes by up-regulating BCL2L2.

Discussion

In the present study, we found that miR-29b was up-regulated in lesional skin and sera from AD patients, and miR-29b up-regulation was positively correlated with AD severity. Moreover, inhibition of miR-29b could protect keratinocytes from IFN-γ-mediated apoptosis, indicating that miR-29b may play an important role in AD progression, providing the future research direction and therapeutic options of treatment for patients with AD.

Increasing evidence emerging to suggest that microRNAs play a crucial role in the pathogenesis of many immune-mediated diseases including AD [9]. For example, it has been shown that miR-143 suppressed IL13-induced down-regulation of epidermal barrier-related proteins (filaggrin, loricrin and others) and inflammation through targeting the IL13 receptor, IL-13R, IL-13R3R keratinocytes [26]. Furthermore, miR-151a may be involved in the pathogenesis of AD by regulating IL12RB2 [27]. However, the biological roles of miRNAs in AD remain largely unknown until now. In this study, we analyzed miRNA expression in healthy and lesional skin of patients with AD by using...
MicroRNA-29b promotes keratinocyte apoptosis in AD

microRNA arrays, and listed a catalogue of miRNAs potentially involved in the regulation and progression of AD. One of the miRNAs with highest over-expression in patients with AD was miR-29b, which is one member of miR-29 family. It has been reported that miR-29 was dysregulated in several disorders including skin diseases [28-30]. For example, miR-29b was up-regulation in E16 and E19 fetal mouse skin and might be thought to mediate several extracellular matrix (ECM) proteins, which contributes to skin scarless phenotype and healing [31]. In this study, we found that miR-29b was up-regulated in the lesional skin and sera of AD patients and miR-29b levels of AD patients were positively correlated with the disease severity score. These results indicate that miR-29b may be involved in the development of AD. However, the underlying mechanism needs to be further delineated.

Recent investigations have greatly increased our understanding of the immunological mechanisms that are involved in the pathogenesis of AD. Although in appropriate immune response, especially excessive Th2 response, is mainly responsible for the development and progress of AD, Th1 cells are also involved in chronic states of the disease [32, 33]. IFN-R, as representative Th1 cytokines, is dominant in the skin of patients with AD, which leads to enhanced and disease-related apoptosis of keratinocytes in the eczematous lesions of patients with AD through up-regulating Fas receptors on keratinocytes [2]. A recent study from Li et al. reported that miR-29b was markedly increased after IFN- treatment in colorectal cancer cell [18], suggesting that IFN-N-8" \o “Yuan, 2015 #1583"miR-29b was mupregulating the expres- sion of miR-29b. In this study, we first investigated whether IFN-regulated the expression of miR-29b in keratinocytes and we observed that miR-29b was up-regulated after IFN- we observe in a time-dependent manner. Thus, we hypothesized that the presence of IFN-a time-dead to keratinocytes apoptosis through up-regulating the expression of miR-29b. As expected, overexpression of miR-29b aggravated the apoptosis induced by IFN-m, whereas inhibition of miR-29b could attenuate the apoptosis induced by IFN-e. These data suggested that knockdown of miR-29b might be a novel therapeutic target to block AD progression. BCL2L2, as a member of the Bcl-2 family, is one of the key regulator of apoptosis [34, 35].

Zhang et al. found that down-regulation of miR-133b suppressed apoptosis of lens epithelial cell by up-regulating BCL2L2 in age-related cataracts [36]. Moreover, a recent study reported that miR-29b directly targeted and inhibited Bcl2L2 gene expression, and then increased neuronal cell death after ischemic brain injury [16]. However, whether BCL2L2 is involved in miR-29b-mediated IFN-v-induced keratinocytes apoptosis remains unknown. Consistent with these findings, our data showed that BCL2L2 was identified as a target gene of miR-29b in keratinocytes. Our data demonstrated that knockdown of miR-29b resulted in increased expression of BCL2L2 at both the protein and the mRNA level, whereas over-expression of miR-29b had an opposite result, which indicated that miR-29b negatively regulated the expression of BCL2L2. Furthermore, we knocked down the expression of BCL2L2 in keratinocytes with si-BCL2L2. We found that siBCL2L2 reversed the inhibitory effect of miR-29b inhibitor on the apoptosis in IFN-treated keratinocytes. These results suggest that IFN-est thad apoptosis of keratinocytes might be partially through miR-29b/BCL2L2 axis, which contributes to the development of AD.

In summary, we found the expression of miR-29b in keratinocytes was upregulated under IFN-under IFN-IFN- ed under IFN-R-29b in kerati- that miR-29b acts as a pro-apoptotic miRNA involved in IFN-IFN-IFN-keratinocytes apoptosis through directly targeting BCL2L2 gene. Based on our findings, we propose that target- ing miR-29b/BCL2L2 pathway can be consid- ered as a potential target in the therapy for AD in the future.

Disclosure of conflict of interest

None.

Address correspondence to: Jinhua Xu, Department of Dermatology, Huashan Hospital, Fudan University, No. 12, Wulumuqi Road, Shanghai 200032, China. Tel: +86-21-52887783; E-mail: xjhhsy@163.com

References

MicroRNA-29b promotes keratinocyte apoptosis in AD


MicroRNA-29b promotes keratinocyte apoptosis in AD


